Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference

2 weeks ago

EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading…

Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference

2 weeks ago

EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading…

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

2 weeks ago

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

2 weeks ago

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

2 weeks ago

From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec.…

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

2 weeks ago

From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec.…

Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility

2 weeks ago

TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for…

Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility

2 weeks ago

TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for…

Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate

2 weeks ago

Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to…

Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate

2 weeks ago

Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to…